Skip Navigation



Hum. Reprod. Advance Access published online on March 27, 2008
Human Reproduction, doi:10.1093/humrep/den095
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
23/7/1594    most recent
den095v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Luque-Ramírez, M.
Right arrow Articles by Escobar-Morreale, H. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luque-Ramírez, M.
Right arrow Articles by Escobar-Morreale, H. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin

Manuel Luque-Ramírez1,2,3, Francisco Álvarez-Blasco1,2, Miguel Giovanni Uriol Rivera1,2,4 and Héctor F. Escobar-Morreale1,2,5

1 Department of Endocrinology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Carretera de Colmenar Viejo Km 9,1., 28034 Madrid, Spain 2 Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Instituto de Salud Carlos III, Spanish Ministry of Health and Consumer Affairs, Madrid, Spain 3 Present address: Department of Endocrinology Hospital Universitario de La Princesa, Madrid, Spain 4 Present address: Department of Nephrology, Hospital Universitario Son Dureta, Palma de Mallorca, Spain

5 Correspondence address. Tel/Fax: +34-91-336-9029; E-mail: hescobarm.hrc{at}salud.madrid.org

BACKGROUND: Serum uric acid levels have emerged as a cardiovascular risk factor, and interventions aimed to decrease its level have been related with an improvement in clinical and non-clinical cardiovascular outcomes.

METHODS: Serum uric acid levels were measured in 40 polycystic ovary syndrome (PCOS) patients and 40 non-hyperandrogenic women matched for BMI and grade of obesity, and were followed-up in 34 PCOS patients who were randomized to an oral contraceptive containing 35 mg ethinyl-estradiol plus 2 mg cyproterone acetate (Diane35 Diario) or metformin (850 mg twice daily) for 24 weeks.

RESULTS: There were no statistically significant differences in uric acid levels between PCOS and non-hyperandrogenic control women. Considering all PCOS and non-hyperandrogenic control women as a whole, obese women showed higher uric acid concentrations than lean and overweight women, and the main determinant of serum uric acid level was the BMI. In PCOS women, Diane35 Diario treatment was related with a decrease in uric acid levels (P = 0.018), whereas no changes were observed with metformin.

CONCLUSIONS: Obesity is the main determinant of serum uric acid concentrations in PCOS patients, yet amelioration of androgen excess with an antiandrogenic contraceptive pill results in a significant decrease in these levels, an effect that is not observed with metformin. ClinicalTrials.gov NLM Identifier: NCT00428311 [ClinicalTrials.gov] .

Key words: obesity/metformin/insulin resistance/hyperandrogenemia/clinical trial

Submitted on October 18, 2007; resubmitted on January 8, 2008; accepted on March 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.